I dont know anything about VRTX so I cannot offer anything up there.
Just my general observation that great data in Phase 2 often leads to nothing more than a failure in Phase 3 (even when the P2 is randomized).
Development stage Biotech in general is nothing more than a gamble. It's not like you can access how many widgets are being sold...you have to rely on the trial and if/how the patients response... and, you never know WTF youre going to get.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.